Summary The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modeling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, […]
Summary Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For […]
Summary Collaborators New Paradigm of HCV Therapy Meeting Participants: Nezam H Afdhal, Rachel Baden, Cynthia Beam, Julie Krop, Clifford Brass, David Brumley, Laurent Castera, Daniel Church, Alfred DeMaria Jr, Kevin Cranston, Lynda Dee, Arnold Doyle, Julia Engstrom-Melnyk, Michael Fried, Camilla Graham, Michael Wong, William Guyer, John G McHutchison, Joe Steele, William Symonds, Ira M Jacobson, Alain Litwin, Anthony Martinez, Andrew Talal, Henry Masur, Douglas Mayers, Ronald C Renaud Jr, Shruti H Mehta, Andrew Muir, Christopher J Myatt, Stanley J Naides, Rick Pesano, William O’Brien, Christos J Petropoulos, Gastón R Picchio, Thierry […]
Summary The UNITAID 2013-2016 Strategy includes the treatment of HIV/AIDS and co-infections as one of six strategic objectives. This scoping report focuses on issues, challenges and opportunities related to one of the most important HIV co-infections—Hepatitis C virus (HCV)—and represents UNITAID’s first effort to gather market intelligence on products for the diagnosis and treatment of […]
Summary Importance Understanding the major health problems in the United States and how they are changing over time is critical for informing national health policy. Objectives To measure the burden of diseases, injuries, and leading risk factors in the United States from 1990 to 2010 and to compare these measurements with those of the 34 […]
Summary Hepatitis C virus (HCV) infection is a leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation. A better understanding of HCV disease progression and the associated cost can help the medical community manage HCV and develop treatment strategies in light of the emergence of several potent anti-HCV therapies. A system dynamic model with 36 […]
Summary Background Jordan lacks statistical data regarding prevalence of HCV. Aim To determine the prevalence of HCV in selected areas of Jordan (north, middle and south of Jordan). Methods A random sample of 700 patients attending health centers was used to determine HCV prevalence. ELISA testing was used to determine HCV-Ab positive cases, which were […]
Summary Background Quantification of the disease burden caused by different risks informs prevention by providing an account of health loss different to that provided by a disease-by-disease analysis. No complete revision of global disease burden caused by risk factors has been done since a comparative risk assessment in 2000, and no previous analysis has assessed […]
Summary Background Globally, hepatitis C virus (HCV) infects ~3% of the population. The objective of this study was to review published work and determine the direct medical costs for diseases associated with HCV infection globally, with the exception of the US. Methods A systematic literature search was conducted to identify studies reporting the costs of […]
Summary There are approximately 100 drugs in development to treat hepatitis C. Over the next decade, a number of new therapies will become available. A good understanding of the cost of hepatitis C sequelae is important for assessing the value of new treatments. The objective of this study was to assess the economic burden data […]
English 
Spanish 
French 
Chinese 
Russian 
Arabic